Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Clinical trials show semaglutide produces an average of ~15% body weight loss at 68 weeks, while tirzepatide has demonstrated up to 20.9% weight loss at 72 weeks. Patients in our medical weight loss program which include nutrition and muscle preservation support lose an average of 1520% of their excess body weight on injectable GLP-1 medications, which is clinically meaningful and can improve conditions like type 2 diabetes, high blood pressure, and sleep apnea
Prescribing Ozempic and Other GLP-1 Drugs Not FDA Approved For Weight Loss to Non-Diabetic Patients A growing number of lawsuits allege that prescribing Ozempic and other GLP-1 drugs to non-diabetic patients for weight loss created preventable harm
Some animal studies also found how milk thistle could reduce the side effects of chemotherapy (8)
Marrades RM, Roca J, Barbera JA, de Jover L, MacNee W, Rodriguez-Roisin R
Vallecillos provides comprehensive care that extends beyond weight management to address the broader health implications of your transformation
